Since the inauguration of the China Anti-tuberculosis Drug Supply Coordination Reserve Bank of China National Tuberculosis Association in December 2016 at Shenyang Hongqi Pharmaceutical Co., Ltd. (hereinafter referred to as Shenyang Hongqi), in order to give full play to the role of the coordinated reserve bank and accelerate the formation of an effective operating mechanism, The supply of anti-tuberculosis drugs nationwide provides a strong guarantee. On February 23, 2017, the Expert Seminar on the Information Platform Construction of the China Anti-tuberculosis Drug Supply Coordination Repository of the China National Tuberculosis Association was held in Xuzhou, Jiangsu. The meeting was presided over by Cheng Shiming, secretary general of the China National Tuberculosis Association. Director Zhou Lin, Associate Researcher Liu Eryong, Director of the Patient Care Department of the China Centers for Disease Control and Prevention Center for Tuberculosis Control and Prevention, Director Du Xin of the Surveillance Department, Director Lu Wei of the Jiangsu Provincial Center for Disease Control and Prevention, Director Zhang Tianhua of the Shaanxi Provincial Tuberculosis Prevention and Control Center and other provincial leaders And experts, as well as more than 20 people including Mr. Xu Zhiming, Li Shaowei and Zhao Weilian from the market and sales department of Shenyang Hongqi, attended the meeting.
The meeting further analyzed the current situation of anti-tuberculosis drug production, supply management and use in my country, and conducted in-depth discussions on issues such as the guarantee of anti-tuberculosis drug supply, price, and drug supply in reserve. At present, the supply of some products of the first-line anti-tuberculosis drugs is insufficient, and there are shortages in some regions or hospitals (such as isoniazid, rifampicin), which poses challenges to the standardized treatment of tuberculosis; due to factors such as environmental protection compliance, the price of drugs varies with the price of raw materials. Rise rapidly. At present, at least 900,000 tuberculosis patients in my country need to use first-line anti-tuberculosis drugs each year, in order to enable patients to obtain standardized treatment, reduce the occurrence of drug-resistant tuberculosis, and also to cope with the tuberculosis epidemic, coordinate supply of local CDC procurement and insufficient inventory or market supply With regard to shortages, it is very necessary for China's anti-tuberculosis drug supply coordination reserve to play its due role.
In order to actively play the role of the reserve, the experts discussed and agreed to establish the "China National Tuberculosis Association Anti-tuberculosis Drug Reserve Drug Information Platform". The platform will announce the types and inventories of medicines in real time; localities will sign purchase agreements through the information platform and follow procedures and regulations as needed, and the reserve warehouse will deliver and supply. It will promote the information management of anti-tuberculosis drugs inventory information release, demand statistics, procurement and supply, delivery acceptance, and payment, and greatly improve efficiency. The China Antituberculosis Association supports local prevention and control departments to actively communicate with various levels of health, accounting, finance and other departments, and use this platform to efficiently alleviate and solve problems such as shortages in drug procurement and supply.
The General Office of the State Council has just issued the "Thirteenth Five-Year Plan for National Tuberculosis Prevention and Control", which emphasizes ensuring the supply of anti-tuberculosis drugs, improving the drug procurement mechanism, and ensuring drug quality, safety, reasonable prices, and adequate supply. It is hoped that the establishment of this information platform will play a positive role in promoting the implementation of my country's tuberculosis prevention and treatment plan.